These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35246604)

  • 21. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
    Noack K; Mahendrarajah N; Hennig D; Schmidt L; Grebien F; Hildebrand D; Christmann M; Kaina B; Sellmer A; Mahboobi S; Kubatzky K; Heinzel T; Krämer OH
    Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
    Jeanteur P
    Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.
    Wang X; Lin Q; Lv F; Liu N; Xu Y; Liu M; Chen Y; Yi Z
    Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of
    Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
    J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
    Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
    Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report.
    Pardo Gambarte L; Franganillo Suárez A; Cornago Navascués J; Soto de Ozaeta C; Blas López C; Atance Pasarisas M; Salgado Sánchez RN; Serrano Del Castillo C; Mata Serna R; Velasco Rodríguez D; López-Lorenzo JL; Llamas-Sillero P; Solán Blanco L
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
    Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
    Jansen JH; Löwenberg B
    Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
    Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
    Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
    Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
    Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).
    Amin HM; Saeed S; Alkan S
    Br J Haematol; 2001 Nov; 115(2):287-97. PubMed ID: 11703323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Tsao T; Konoplev S; Shi Y; Ling X; Watt JC; Tsutsumi-Ishii Y; Ohsaka A; Nagaoka I; Issa JP; Kogan SC; Andreeff M
    Cancer Biol Ther; 2007 Dec; 6(12):1967-77. PubMed ID: 18075297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
    Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
    Jing Y; Waxman S
    Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.